This site is intended for Healthcare professionals.
×

Perioperative beta-blockers therapy for non-cardiac surgery: A focused update of ACC/AHA Guidelines

................................ Advertisement ................................


speciality medical dialogues

The American College of Cardiology and The Americal Heart Association has released an update of the guidelines on perioperative cardiovascular evaluation for non-cardiac surgery. Lates update focuses on perioperative beta-blocker therapy. The guidelines were published in the Journal of American College of Cardiology.

The purpose of this guideline update was to address the issue of perioperative beta-blockade for non-cardiac surgery which has taken on increased importance since the guidelines for perioperative cardiovascular evaluation for non-cardiac surgery was released in 2002.  The National Quality Forum and the Surgical Care Improvement Project have both identified perioperative beta-blockade as a quality measure. The guideline update was published given the importance of these quality measures for both public reporting and eventual pay-for-performance, and the recent series of publications on the subject.

Following are the recommendations for  Beta-Blocker Medical Therapy

................................ Advertisement ................................

  • 1 Beta-blockers should be continued in patients undergoing surgery who are receiving beta-blockers to treat angina, symptomatic arrhythmias, hypertension, or other ACC/AHA guideline indications. 
  • 2 Beta-blockers should be given to patients undergoing vascular surgery at high cardiac risk owing to the finding of ischemia on preoperative testing.

Class IIa (weight of evidence/opinion is in favor of usefulness/efficacy)

................................ Advertisement ................................

  • 1 Beta-blockers are probably recommended for patients undergoing vascular surgery in whom preoperative assessment identifies coronary heart disease.
  • Beta-blockers are probably recommended for patients in whom preoperative assessment for vascular surgery identifies high cardiac risk as defined by the presence of multiple clinical risk factors.*

  • Beta-blockers are probably recommended for patients in whom preoperative assessment identifies coronary heart disease or high cardiac risk as defined by the presence of multiple clinical risk factors* and who are undergoing intermediate- or high-risk procedures as defined in these guidelines.

    ................................ Advertisement ................................

Class IIb (usefulness/efficacy is less well established by evidence/opinion)

  • Beta-blockers may be considered for patients who are undergoing intermediate- or high-risk procedures as defined in these guidelines, including vascular surgery, in whom preoperative assessment identifies intermediate cardiac risk as defined by the presence of a single clinical risk factor.* 

  • Beta-blockers may be considered in patients undergoing vascular surgery with low cardiac risk (as defined in these guidelines) who are not currently on beta-blockers. 

Class III (conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective, and in some cases may be harmful)

  • 1 Beta-blockers should not be given to patients undergoing surgery who have absolute contraindications to beta-blockade.

For further reference, click on the link

https://doi.org/10.1161/CIRCULATIONAHA.109.192690




Source: self

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted
  1. user
    Dr Valluri Ramararo May 30, 2019, 6:21 pm

    Nice article Thanks .

................................ Advertisement ................................